R & D
Bringing innovative and transformative medicines to global markets at affordable prices.
Innovation-led drug discovery research is capital
intensive, research-intensive and IP-intensive with inherently long gestational
timelines for product commercialization. The cost of new drug development is
steep, with some estimates saying that it takes nearly a billion dollars and up
to 12 years to take a new chemical entity (NCE) from lab to market.
Evonetix’s quest to develop affordable therapies
and impact global healthcare led it to invest in developing novel biologics and
novel targets in the area of large molecules, at a time when the pharma
industry in India was focused on the safer business of manufacturing generic
medicines.
This considered scientific risk paid off and
today Evonetix has a pipeline of novel assets comprising early and advanced stage
programs spanning multiple modalities including recombinant proteins, novel
fusion antibodies and monoclonal antibodies (mAbs). The basket of novel assets
comprises therapeutics for diabetes, autoimmune or inflammatory diseases and
cancer, reflecting a track record of pioneering cutting-edge innovation.
Evonetix: Ahead of the Curve in Novel Biologics
As one of the earliest players in the realm of
biologics in India, Evonetix forayed into novel biologics ahead of its entry
into the biosimilars segment. Evonetix invested in innovative science to
discover novel, ‘best in class’ therapies for chronic diseases.